We are studying a new treatment called ABBV-CLS-484 for people with advanced tumor cancer. The trial will explore its effects alone and in combination with other therapies.
We are investigating the safety of a new drug, GB-0895, in patients with mild to moderate asthma and those with COPD. This study aims to understand how well the drug is tolerated in these groups.
We are studying a new T cell therapy for people with active systemic lupus erythematosus to see if it is safe and effective. This research aims to understand how it affects disease activity and overall health.
We are testing a new vaccine for adults with hepatitis B to see if it is safe and how well it boosts the immune response. The study will also check if it helps reduce the virus in the body.
We are assessing how the oral medication ABBV-453 affects adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The study focuses on understanding its side effects and how it moves through the body.
We are testing a new treatment for patients with systemic lupus erythematosus that has not responded to standard therapies. The goal is to see if this new approach can provide better outcomes.
We are studying a new treatment for men with advanced prostate cancer to see if it is safe and effective. This trial includes men who have been treated before and those who have not.
We are evaluating a new treatment called TERN-701 for individuals with chronic myeloid leukemia. The study aims to assess its safety and how well it works compared to existing options.
We are testing a new cell therapy to see if it helps patients with acute respiratory distress syndrome caused by viruses like COVID-19 and influenza. The study will evaluate its safety and effectiveness in reducing severe immune responses.
We are evaluating a new treatment for adults with Frontotemporal Dementia linked to GRN or C9orf72 mutations. The study aims to understand its safety and how well it works in this specific group.
We are studying a new treatment using Glofitamab after Obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Our goal is to evaluate its safety and effectiveness compared to standard treatments.
We are testing a new nasal treatment to see if it is safe and effective for patients. This study also explores how it affects the nasal microbiome.
We are investigating the safety and effectiveness of BGB-11417 alone and with other medications for patients with relapsed or refractory multiple myeloma. This study aims to find the best treatment options for those with a specific genetic marker.
We are evaluating the safety of MAQ-001, both alone and with other treatments, for patients with advanced cancers. This study aims to understand how well it works in this patient group.
We are studying whether linvoseltamab is safe and effective for adults with relapsed or refractory systemic light chain amyloidosis. The trial will help us understand its impact on blood response and overall health.
We are testing a new CAR T cell treatment for people with relapsing or progressive multiple sclerosis. The goal is to see if it can improve symptoms and overall health.
We are investigating whether a new imaging method can predict how well early-stage high-risk triple-negative breast cancer patients respond to chemotherapy and immunotherapy. This may help tailor treatments more effectively.
We are investigating whether Ifenprodil can help repair nerve damage in people with Multiple Sclerosis. This study aims to see if it may improve symptoms and overall function.
We are investigating the safety and effectiveness of a new injectable treatment for patients with relapsed or refractory Multiple Myeloma. This study aims to understand how well it works compared to existing therapies.
We are testing a new treatment called DS-3939a to see if it is safe and effective for people with advanced solid tumors. This study aims to understand how well it works and its effects on tumor tissue.